<?xml version="1.0" encoding="utf-8"?>
<items><story><date>16:40 03 January 2007 (UTC)</date><text>LOS ANGELES Jan 3 Genaera Corp. GENR.O said
on Wednesday it will cut its workforce by 30 percent as it
terminates development of Evizon as a treatment for wet
age-related macular degeneration and focuses resources on
development of trodusquemine for the treatment of obesity. The company said it has also engaged Banc of America
Securities LLC as its financial advisor to assist in its review
of strategic alternatives. Genaera said it expects to initiate a Phase I clinical
study of trodusquemine in the first half of 2007. (Reporting by Deena Beasley; Reuters Messaging:
deena.beasley@reuters.com@reuters.net; 1-213-955-6746))</text><link>http://www.reuters.com/article/2007/01/03/genaera-idUSWEN172320070103</link><sectors></sectors><title>genaera to end evizon program , cut workforce 30 pct</title></story></items>